Down 53%, Should You Still Buy CoreWeave's (CRWV) Stock?

CoreWeave shares have fallen about 53% from their $183.58 June 2025 peak to roughly $86, despite 2025 revenue rising 168% to $5.1B and adjusted EBITDA increasing 154% to $3.1B. Analysts project 2026 revenue of $12.9B (+151%) and adjusted EBITDA of $7.5B (+144%), supported by a $104B contracted revenue backlog that was up 246% year over year at Q2 2026. The investment case is tempered by persistent GAAP losses, repeated equity and debt issuance, and a very high 14.3 debt-to-equity ratio, making the stock a high-growth but volatile valuation-driven opportunity.

Analysis

The apparent EBITDA multiple is a poor valuation anchor for CRWV because the business economically consumes GPUs and data-center equipment far faster than adjusted EBITDA captures. The investable question is whether contracted cash receipts exceed interest, maintenance/replacement capex, and collateral requirements as the debt stack reprices; a backlog does not eliminate this refinancing risk if counterparties retain deferral, cancellation, or ramp-delay flexibility. At current leverage, even a modest utilization shortfall can produce disproportionate equity downside through both lower EBITDA and a higher required equity-risk premium.

Customer concentration creates a non-linear competitive threat: MSFT, META, and AMZN can satisfy incremental AI demand internally, with proprietary silicon or owned capacity, while retaining CRWV as a burst-capacity vendor only. That would pressure renewal pricing before it necessarily shows up in headline revenue, particularly as GPU supply normalizes. NVDA is the cleaner second-order beneficiary only while CRWV continues funding hardware purchases; a capital-spending slowdown at CRWV would be a negative incremental demand signal for NVDA, albeit immaterial to NVDA's diversified base.

The consensus error is likely treating rapid reported growth and backlog conversion as equivalent to durable free-cash-flow generation. The bull case becomes credible over 6-18 months only if CRWV demonstrates stable utilization, rising operating cash flow after interest, and funding capacity without equity issuance. Near term, this is more a credit/liquidity trade than a growth-stock rerating: quarterly capex commitments, interest expense, customer prepayments, and any secured-debt issuance matter more than adjusted EBITDA guidance.

Key Decisions for Investors

• Do not initiate a core CRWV long at current levels; place a 1-3 month event-driven watch on the next earnings release. Buy only if operating cash flow after cash interest improves sequentially, utilization/contracted capacity is disclosed as stable or rising, and management funds expansion without a material equity raise; otherwise the equity remains vulnerable to a refinancing-driven drawdown.
• For a defined-risk bullish expression, use a small CRWV call spread 6-9 months out rather than common equity, sized assuming a full premium loss. Enter only after results validate backlog-to-revenue conversion; the upside catalyst is financing clarity, while a new dilutive issuance or reduced capex guidance invalidates the thesis.
• Maintain NVDA exposure separately from CRWV rather than using CRWV as a proxy for GPU demand. Set an alert for any CRWV capex reduction, delayed deployments, or vendor-financing disclosure: this would be a modest near-term negative read-through for NVDA and a stronger signal to avoid CRWV.
• Consider a tactical long MSFT or META versus CRWV pair over the next 3-6 months if CRWV reports weaker utilization or pricing. Hyperscalers can redirect workloads to owned infrastructure and absorb AI capacity volatility; cover the pair if CRWV demonstrates improving free-cash-flow conversion or announces long-duration, non-cancelable customer commitments with prepayments.